NASDAQ · Biotechnology

Beam Therapeutics Inc. (BEAM) Stock

$23.47 -5.10% NASDAQ: BEAM Healthcare

Valuation

MetricValue
Price$23.47
Market Cap$2.42B
P/E Ratio-29.88
P/B Ratio2.39
P/S Ratio16.15
EPS (TTM)$0.00
52-Week High$38.26
52-Week Low$20.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-7.70%
ROA-6.16%
ROCE-28.96%
Gross Margin-273.57%
Operating Margin-274.29%
Net Margin-54.75%
Debt/Equity0.23
Current Ratio13.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$52.0M$61.0M$378.0M$64.0M$140.0M
Operating Profit$-392.0M$-338.0M$-176.0M$-416.0M$-384.0M
Net Profit$-371.0M$-289.0M$-133.0M$-377.0M$-80.0M
EPS$-5.77$-4.13$-1.72$-4.58$-0.81
Op Margin-757.0%-555.6%-46.7%-654.3%-274.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.5B$1.3B$1.5B$1.1B$1.5B
Total Liabilities$648.0M$608.0M$478.0M$370.0M$243.0M
Cash$560.0M$233.0M$436.0M$282.0M$295.0M
Borrowings$148.0M$179.0M$173.0M$161.0M$294.0M

Latest News

Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? Simply Wall St. · Jul 9, 2026 NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? Zacks · Jul 9, 2026 Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle Investor's Business Daily · Jul 8, 2026 Update: Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise MT Newswires · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-66.0M$23.0M$-149.0M$-347.0M$-345.0M
Investing Cash Flow$-341.0M$-510.0M$38.0M$176.0M$-136.0M
Financing Cash Flow$1.0M$6.0M$9.0M$0$0
Net Cash Flow$396.0M$-327.0M$199.0M$-155.0M$12.0M
Free Cash Flow$-113.0M$-26.0M$-183.0M$-356.0M$-360.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.40
EV / EBITDA-42.26
FCF Yield-14.79%
Quick Ratio14.57
Interest Coverage-35.53
Return 1Y23.68%
Return 3Y-16.93%
Return 5Y-71.16%

Ownership

Insiders Held1.40%
Institutions Held106.90%
Institutions Float Held108.41%
Institutional HolderSharesReport Date
FMR, LLC12,452,1992026-03-31
ARK Investment Management, LLC12,133,4332026-03-31
Farallon Capital Management LLC10,134,6962026-03-31
Blackrock Inc.8,487,5692026-03-31
State Street Corporation5,699,2652026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLOAllogene Therapeutics, Inc. $1.31 -2.24% -2.24 $452.59M 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%
CRBUCaribou Biosciences, Inc. $0.47 +1.12% -1.13 $50.38M 0.00%
CRSPCRISPR Therapeutics AG $49.25 -4.41% -11.62 $4.76B 0.00%
DTILPrecision BioSciences, Inc. $5.77 -6.48% -2.26 $159.26M 0.00%

About Beam Therapeutics Inc.

Beam Therapeutics Inc. (BEAM) stock trades at $23.47 with a market capitalization of $2.42B. The stock is valued at a negative price-to-earnings (P/E) ratio of -29.88, reflecting a net loss over the last twelve months, price-to-book of 2.39, price-to-sales of 16.15. Over the past 52 weeks the stock has ranged between $20.23 and $38.26, and currently trades 38.7% below its 52-week high.

On profitability, Beam Therapeutics Inc. generates a return on equity (ROE) of -7.70% (negative, reflecting a net loss), return on capital employed of -28.96%, an operating margin of -274.29%, a net profit margin of -54.75%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.